600196 復星醫藥
按盤價 
25.370 +1.260 (+5.226%) | 2025/03 - 三個月 人民幣(K¥) | 與去年同期 比較 | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | ||
| 營業總收入 | 9,420,323 | -7.26% | 41,067,196 | 41,399,540 | 43,951,547 | 39,011,184 | |
| 減：營業總成本 | 9,130,342 | -4.12% | 39,397,512 | 41,284,077 | 41,346,264 | 37,093,266 | |
| 其中:營業成本 | 4,920,296 | -3.10% | 21,365,574 | 21,595,309 | 23,169,690 | 20,229,785 | |
| 財務費用 | 277,183 | -1.08% | 1,110,518 | 984,323 | 647,403 | 464,022 | |
| 資產減值損失 | (10,549) | -279.24% | (96,570) | (219,742) | (272,488) | (829,873) | |
| 公允價值變動收益 | (281,745) | 1,299.12% | (115,939) | (427,380) | (2,498,368) | 352,299 | |
| 投資收益 | 1,281,382 | 281.87% | 2,104,607 | 3,501,993 | 4,377,843 | 4,623,826 | |
| 其中：對聯營企業和合營企業的投資收益 | 385,776 | 16.79% | 1,643,839 | 2,184,849 | 1,835,146 | 1,789,137 | |
| 營業利潤 | 1,358,771 | 33.03% | 4,245,104 | 3,307,508 | 4,656,656 | 6,302,568 | |
| 利潤總額 | 1,347,542 | 32.32% | 4,169,282 | 3,264,568 | 4,574,382 | 6,042,671 | |
| 減：所得稅費用 | 405,976 | 74.84% | 656,841 | 369,504 | 626,917 | 1,066,401 | |
| 淨利潤 | 941,566 | 19.76% | 3,512,440 | 2,895,063 | 3,947,464 | 4,976,269 | |
| 減：非控股權益 | 176,809 | 0.18% | 742,554 | 508,798 | 216,660 | 247,559 | |
| 股東淨利潤 | 764,758 | 25.42% | 2,769,887 | 2,386,266 | 3,730,805 | 4,728,711 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 0.290 | 26.09% | 1.040 | 0.890 | 1.430 | 1.850 | |
| 每股派息 (元) * | -- | -- | 0.320 | 0.270 | 0.420 | 0.560 | |
| 每股淨資產 (元) * | 17.940 | 3.45% | 17.700 | 17.110 | 16.684 | 15.292 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 30/05/2025 16:29 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
